CME: Hypoactive Sexual Desire Disorder: Counseling, Diagnosis, Treatment

Counseling Your Patients About Hypoactive Sexual Desire Disorder and Advances in its Diagnosis and Treatment

Counseling Your Patients About Hypoactive Sexual Desire Disorder and Advances in its Diagnosis and Treatment
Talking about sexual health with your female patients isn’t always easy, but there are strategies that can help you boost their overall well-being.

Available credits: 1.00

Time to complete: 60 Minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Even though hypoactive sexual desire disorder (HSDD) is the most common female sexual dysfunction and occurs in women of all ages, it continues to be under-diagnosed and under-managed. The major cause of this is a lack of physician-patient communication regarding female sexual health and functioning.

    To address this communication gap, this journal supplement addresses the areas of concern that inhibit women’s healthcare clinicians in effectively addressing HSDD and discusses how to implement strategies that will improve both the sexual health of patients with HSDD and their overall sense of well-being.


  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.


    Sheryl A. Kingsberg, PhD
    Professor of Reproductive Biology and Psychiatry
    Case Western Reserve University School of Medicine
    Cleveland, OH

    Financial Disclosure:
    Consulting Fees: AMAG Pharmaceuticals, Dare, Emotional Brain, Endoceutics, Palatin, Strategic Science Technologies, Valeant Pharmaceuticals 
    Commercial Interest Speakers Bureau: AMAG Pharmaceuticals, Therapeutics MD
    Contracted Research: AMAG Pharmaceuticals, Endoceutics, Palatin 
    Ownership Interest: Viveve

    Sharon J. Parish, MD                                                                                
    Professor of Medicine in Clinical Psychiatry
    Professor of Clinical Medicine
    Weill Cornell Medical College
    New York, NY

    Financial Disclosure:
    Advisory Board: AMAG Pharmaceuticals, Duchesnay Pharmaceuticals
    Consultant: Dare, JTS Therapeutics, Proctor and Gamble, Strategic Science Technologies, Therapeutics MD

    David J. Portman, MD
    Director Emeritus, Columbus Center for Women’s Health Research
    Adjunct Instructor of Obstetrics and Gynecology
    Ohio State University
    Columbus, OH

    Financial Disclosure:
    Salary: Sermonix Pharmaceuticals
    Consulting Fees: AMAG Pharmaceuticals, ITF
    Commercial Interest Speakers Bureau: AMAG Pharmaceuticals
    Ownership Interest: Sermonix Pharmaceuticals

    James A. Simon, MD, CCD, NCMP, IF, FACOG                                                                    
    Clinical Professor George Washington University
    IntimMedicine SpecialistsTM
    Washington, DC

    Financial Disclosure:
    Advisory Board/Consultant: AbbVie, Inc., Allergan, Plc, AMAG Pharmaceuticals, Inc., Amgen, Ascend Therapeutics, Bayer HealthCare Pharmaceuticals Inc., CEEK Enterprises, LLC, Covance Inc., Dare´ Bioscience, Duchesnay USA, Hologic Inc., KaNDy/NeRRe Therapeutics Ltd., Mitsubishi Tanabe Pharma Development America, Inc., ObsEva SA, Palatin Technologies, Sanofi S.A., Shionogi Inc., Sprout2 Inc., TherapeuticsMD
    Commercial Interest Speakers Bureau: AbbVie, Inc., AMAG Pharmaceuticals, Inc., Duchesnay USA, Novo Nordisk, Shionogi Inc., TherapeuticsMD
    Grants/Research: AbbVie, Inc., Allergan, Plc, Agile Therapeutics, Bayer Healthcare LLC., Endoceutics, Inc., GTx, Inc., Ipsen, Myovant Sciences, New England Research Institute, Inc., ObsEva SA, Palatin Technologies, Symbio Research, Inc., TherapeuticsMD, Viveve Medical
    Stock Shareholder: Sermonix Pharmaceuticals


    • Kahlil Demonbreu, DNP, RNC-OB, WHNP-BC, FAAN receives consulting fees from Hologic and Symbiomix Therapeutics.
    • Carole Drexel, PhD, CHCP has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Ashley Rosenthal has nothing to disclose.
    • Robert Schneider, MSW has nothing to disclose.


  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify the symptoms of hypoactive sexual desire disorder
    • Cite barriers in their clinical practice that inhibit the appropriate diagnosis and management of HSDD
    • Identify the screening tools that allow for accurate diagnosis of HSDD
    • Explain causal factors for HSDD and common co-morbid conditions
    • Identify the therapeutic modalities available to manage HSDD including their benefits and potential side effects
  • Target Audience

    This activity is designed to meet the educational needs of the obstetrician and gynecologist, family physician, internal medicine physician, physician assistant, nurse practitioner, and certified nurse midwife.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider


    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from AMAG Pharmaceuticals, Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments


We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free